Target Markets

QRxPharma is a clinical-stage specialty pharmaceutical company with a core focus on the development and commercialisation of pain therapy products.  The market for treatment of moderate to severe pain is commonly classified as a ‘specialty pharmaceutical’ market, and is served by a number of pharmaceutical firms in the pain therapy area. Opioids are highly regulated by authorities such as the FDA and the Drug Enforcement Agency (DEA) in the US, and the Therapeutic Goods Administration (TGA) in Australia.

The first target market for QRxPharma’s pain therapy drugs is the US. This is the largest and most commercially attractive market for pain drugs in the world. The total market value of prescription opioid sales in the US was US$8.4 billion in 2007, just over 70% of the global total. The opioid market in the US has grown on average by 13% each year since 2001.

The market for opioid drugs can be broken up into drugs for the immediate relief of pain (immediate release or IR) and drugs for the relief of pain over time (controlled or extended release CR or ER), which is typically a number of hours. MoxDuo® IR (Q8003 IR) is an immediate release drug and MoxDuo® CR (Q8011 CR) is a controlled release drug.